Literature DB >> 18219447

Progesterone pretreatment enhances serotonin-stimulated BDNF gene expression in rat c6 glioma cells through production of 5alpha-reduced neurosteroids.

Kyoji Morita1, Song Her.   

Abstract

Tricyclic antidepressants and selective serotonin reuptake inhibitors are considered in theory to induce the outflow of neurotransmitters, norepinephrine, and serotonin from the synapses as a consequence of inhibiting their reuptake into the nerve terminals, resulting in the stimulation of glial cells surrounding the synapses in the brain. Then, we have investigated the direct actions of neurotransmitters on glial cell metabolism and function using rat C6 glioma cells as an in vitro model system and suggested that these neurotransmitters induce their differentiation probably through the production of 5alpha-reduced neurosteroids. On the other hand, the stimulation of the glioma cells with serotonin has been reported to enhance brain-derived neurotrophic factor (BDNF) gene expression, which may be closely related to the beneficial effects of antidepressant drugs. In the present study, to evaluate BDNF expression in differentiated glial cells, the glioma cells were pretreated with progesterone, and the effect of serotonin on BDNF messenger RNA levels in these cells was examined. Progesterone pretreatment enhanced the stimulatory action of serotonin on BDNF gene expression, and the enhancement of serotonin action observed in the cells pretreated with progesterone was almost completely abolished by finasteride, an inhibitor of the enzyme involved in the production of 5alpha-reduced neurosteroids. These findings propose the possibility that neurosteroid-mediated glial cell differentiation may result in the enhancement of serotonin-stimulated BDNF gene expression, which is considered to contribute to the survival, regeneration, and plasticity of neuronal cells in the brain, and hence, leading to the improvement of mood disorders and other symptoms in depressive patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18219447     DOI: 10.1007/s12031-007-9034-6

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  29 in total

1.  Neuronal plasticity and survival in mood disorders.

Authors:  R S Duman; J Malberg; S Nakagawa; C D'Sa
Journal:  Biol Psychiatry       Date:  2000-10-15       Impact factor: 13.382

2.  Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects.

Authors:  Brian A Hoshaw; Jessica E Malberg; Irwin Lucki
Journal:  Brain Res       Date:  2005-03-10       Impact factor: 3.252

Review 3.  BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis.

Authors:  Clive R Bramham; Elhoucine Messaoudi
Journal:  Prog Neurobiol       Date:  2005-06       Impact factor: 11.685

4.  Serotonergic 5-HT2A receptor stimulation induces steroid 5alpha-reductase gene expression in rat C6 glioma cells via transcription factor Egr-1.

Authors:  Kyoji Morita; Hideki Arimochi; Song Her
Journal:  Brain Res Mol Brain Res       Date:  2005-10-03

5.  Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects.

Authors:  Arvind Govindarajan; B S Shankaranarayana Rao; Deepti Nair; Mimi Trinh; Nadya Mawjee; Susumu Tonegawa; Sumantra Chattarji
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-21       Impact factor: 11.205

6.  Physical activity and antidepressant treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the rat hippocampus.

Authors:  A A Russo-Neustadt; R C Beard; Y M Huang; C W Cotman
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

7.  Cyclic AMP decreases the expression of a neuronal marker (GAD67) and increases the expression of an astroglial marker (GFAP) in C6 cells.

Authors:  J Segovia; G M Lawless; N J Tillakaratne; M Brenner; A J Tobin
Journal:  J Neurochem       Date:  1994-10       Impact factor: 5.372

8.  Adrenergic activation of steroid 5alpha-reductase gene expression in rat C6 glioma cells: involvement of cyclic amp/protein kinase A-mediated signaling pathway.

Authors:  Kyoji Morita; Hideki Arimochi; Yoshihiro Tsuruo
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

9.  Effect of progesterone, testosterone and their 5 alpha-reduced metabolites on GFAP gene expression in type 1 astrocytes.

Authors:  R C Melcangi; M A Riva; F Fumagalli; V Magnaghi; G Racagni; L Martini
Journal:  Brain Res       Date:  1996-03-04       Impact factor: 3.252

10.  Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus.

Authors:  M Nibuya; E J Nestler; R S Duman
Journal:  J Neurosci       Date:  1996-04-01       Impact factor: 6.167

View more
  5 in total

1.  Progesterone increases the release of brain-derived neurotrophic factor from glia via progesterone receptor membrane component 1 (Pgrmc1)-dependent ERK5 signaling.

Authors:  Chang Su; Rebecca L Cunningham; Nataliya Rybalchenko; Meharvan Singh
Journal:  Endocrinology       Date:  2012-07-09       Impact factor: 4.736

2.  Trichostatin A enhances glutamate transporter GLT-1 mRNA levels in C6 glioma cells via neurosteroid-mediated cell differentiation.

Authors:  Mari Itoh; Takara Hiroi; Naoyoshi Nishibori; Takefumi Sagara; Song Her; Mi-Sook Lee; Kyoji Morita
Journal:  J Mol Neurosci       Date:  2012-06-19       Impact factor: 3.444

3.  Progesterone Changes VEGF and BDNF Expression and Promotes Neurogenesis After Ischemic Stroke.

Authors:  Chao Jiang; Fangfang Zuo; Yuejuan Wang; Hong Lu; Qingwu Yang; Jian Wang
Journal:  Mol Neurobiol       Date:  2016-01-08       Impact factor: 5.590

4.  Trichostatin A stimulates steroid 5alpha-reductase gene expression in rat C6 glioma cells via a mechanism involving Sp1 and Sp3 transcription factors.

Authors:  Song Her; Mi-Sook Lee; Kyoji Morita
Journal:  J Mol Neurosci       Date:  2009-09-02       Impact factor: 3.444

Review 5.  Molecular actions of sex hormones in the brain and their potential treatment use in anxiety disorders.

Authors:  Miriam Pillerová; Veronika Borbélyová; Michal Pastorek; Vladimír Riljak; Július Hodosy; Karyn M Frick; L'ubomíra Tóthová
Journal:  Front Psychiatry       Date:  2022-09-08       Impact factor: 5.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.